Media center

Press Releases
Publications
Media Coverage
Events

Press Releases

July 21, 2022

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Press Releases

July 21, 2022

Acticor Biotech obtains "PRIME" status from the European Medicines Agency for glenzocimab in the treatment of stroke

Press Releases

June 29, 2022

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Press Releases

June 29, 2022

Acticor Biotech announces the issuance of a patent in Europe for glenzocimab, its innovative product for the treatment of cardiovascular emergencies

Press Releases

May 9, 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Press Releases

May 9, 2022

Presentation of positive results from the ACTIMIS Phase 1b/2a study in stroke at ESOC 2022

Press Releases

April 27, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Press Releases

April 27, 2022

Availability of the 2021 Universal registration document and the preparatory documents for the combined general meeting of May 12, 2022

Press Releases

March 30, 2022

2021 full year financial results and update on clinical development

Press Releases

March 30, 2022

2021 full year financial results and update on clinical development

Press Releases

March 8, 2022

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Press Releases

March 8, 2022

Acticor Biotech announces the appointment of Corinne Le Goff to the Board of Directors as an independent director

Press Releases

February 22, 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Press Releases

February 22, 2022

Acticor Biotech announces positive results from its ACTIMIS phase 1b/2a study in patients with Acute Ischemic Stroke (AIS)

Press Releases

February 2, 2022

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Press Releases

February 2, 2022

Results of the Phase 2 GARDEN study in COVID-19-related acute respiratory distress syndrome and exclusive interview with Acticor Biotech management

Press Releases

January 12, 2022

Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux

Press Releases

January 12, 2022

Acticor Biotech announces coverage of its stock by Gilbert Dupont and Kepler Cheuvreux

Press Releases

November 4, 2021

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Press Releases

November 4, 2021

Acticor Biotech Announces FDA Acceptance of IND Application for glenzocimab in Acute Ischemic Stroke

Press Releases

October 30, 2021

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Press Releases

October 30, 2021

Acticor Biotech is the laureate of the Prix Galien Medstartup award in the category “BEST COLLABORATION IN THE PHARMACEUTICAL OR BIOTECHNOLOGY INDUSTRY”

Press Releases

October 27, 2021

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Press Releases

October 27, 2021

Success of Acticor Biotech’s Initial Public Offering on the Euronext Growth® market with €15.5 million raised

Press Releases

October 15, 2021

Acticor Biotech launches its Initial Public Offering on the Euronext Growth® market in Paris

Press Releases

October 15, 2021

Acticor Biotech launches its Initial Public Offering on the Euronext Growth® market in Paris

Press Releases

October 13, 2021

Acticor Biotech Announces the First Patient in ACTISAVE, its adaptive Phase 2/3 Efficacy Study in Acute Ischemic Stroke

Press Releases

October 13, 2021

Acticor Biotech Announces the First Patient in ACTISAVE, its adaptive Phase 2/3 Efficacy Study in Acute Ischemic Stroke

Press Releases

September 28, 2021

ACTICOR BIOTECH announces its projected IPO on the Euronext Growth® market in Paris

Press Releases

September 28, 2021

ACTICOR BIOTECH announces its projected IPO on the Euronext Growth® market in Paris

Press Releases

July 22, 2021

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Press Releases

July 22, 2021

Acticor Biotech Announces the Completion of Enrollment in its GARDEN clinical trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

Press Releases

July 1, 2021

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Press Releases

July 1, 2021

Acticor Biotech Announces the Completion of Enrollment in ACTIMIS, its Key Phase 1b/2a Safety Study

Press Releases

June 15, 2021

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Press Releases

June 15, 2021

Acticor Biotech Announces appointment of Mr Alain Munoz as Chairman of the Board of Directors and Mrs Sophie Binay and Mr Yannick Pletan as General Managers

Press Releases

December 22, 2020

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Press Releases

December 22, 2020

Acticor Biotech Announces the Recruitment of the First Patient in its Phase 2 GARDEN Study in COVID-19_related ARDS

Press Releases

October 1, 2020

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Press Releases

October 1, 2020

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Press Releases

January 21, 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

Press Releases

January 21, 2020

ACTICOR BIOTECH INTEGRE LE 1 ER FRENCH TECH 120

Press Releases

November 6, 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Press Releases

November 6, 2019

ACTICOR BIOTECH RAISES €7M IN ADDITION TO ITS SERIES B FINANCING, NOW COMPLETED AT €22,3M

Press Releases

November 5, 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Press Releases

November 5, 2019

ACTICOR BIOTECH PARTNER OF THE BOOSTER CONSORTIUM DEDICATED TO MANAGEMENT AND NEW TREATMENTS OF STROKE IN EMERGENCY SITUATIONS

Press Releases

August 21, 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Press Releases

August 21, 2018

A +60M€ regional development and commercialisation agreement signed with China Medical System Holding Limited®

Press Releases

June 14, 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Press Releases

June 14, 2018

ACTICOR BIOTECH CONFIRMS SIMBEC-ORION TO MAKE ITS FIRST IN PATIENT STUDY IN ACUTE ISCHEMIC STROKE

Press Releases

April 25, 2018

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Press Releases

April 25, 2018

ACTICOR BIOTECH ANNOUNCES THAT THE EUROPEAN MEDICINES AGENCY CLEARS THE ROUTE FOR A PHASE II OF ITS ACT017 PRODUCT IN STROKE

Press Releases

February 5, 2018

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Press Releases

February 5, 2018

ACTICOR BIOTECH COMPLETED ITS PHASE I CLINICAL TRIAL WITH ACT017 ACHIEVING ITS SAFETY AND TOLERABILITY PRIMARY ENDPOINTS

Press Releases

January 4, 2018

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Press Releases

January 4, 2018

Acticor Biotech announces the closing of a €1,7 million equity financing led by Primer Capital

Press Releases

December 20, 2017

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Press Releases

December 20, 2017

Acticor Biotech Announces Appointment of Dr Yannick Plétan as Chief Medical Officer

Press Releases

October 17, 2017

Acticor Biotech first-in-human clinical trial in healthy volunteers

Press Releases

October 17, 2017

Acticor Biotech first-in-human clinical trial in healthy volunteers

Press Releases

May 18, 2017

Acticor reached the milestones triggering the second payment in the Research Agreement with its pharma partner Mediolanum

Press Releases

May 18, 2017

Acticor reached the milestones triggering the second payment in the Research Agreement with its pharma partner Mediolanum

Press Releases

February 23, 2017

Acticor Biotech has selected its Contract Research Organisation to manage Clinical Study Phase I

Press Releases

February 23, 2017

Acticor Biotech has selected its Contract Research Organisation to manage Clinical Study Phase I

Navigation
CompanyOur ProductPipelineAbout strokeMedia
Contact Us
ContactFollow us on LinkedInFollow us on Twitter

Acticor Biotech
Wojo Building
82, avenue du Maine
75014 Paris

+33 (0)6 76 23 38 13

© 2021 Acticor Biotech SA
Legal mentionsPrivacy Policy
email:
contact@acticor-biotech.com